Crossmark

Adjuvant immunotherapy for renal cell carcinoma: understanding complexity, embracing uncertainty, making a difference

Published Online: 2026-04-29

Authors

Campi, Riccardo https://orcid.org/0000-0001-5237-0888
Amparore, Daniele

,

Palumbo, Carlotta

Marandino, Laura

Wu, Zhenjie

Roussel, Eduard

Marchioni, Michele

Pandolfo, Savio Domenico
License Information

Text and Data Mining valid from 2026-04-29

Version of Record valid from 2026-04-29
More Information

Article History

First Online: 29 April 2026

Competing interests

: R.C. has received honoraria for advisory roles and travel grants from Telix Pharmaceuticals, Ipsen and MSD. D.A. declares no competing interests.

Document is current